Montpellier-based SeqOne Genomics has secured €20 million in an oversubscribed growth funding round to accelerate its mission of transforming genomic diagnostics through artificial intelligence. The round was led by new investor Supernova Invest, with continued participation from existing investors Elaia, Omnes, and Merieux Equity Partners.
The funding represents a significant milestone for the French deep-tech company, which has positioned itself as a pioneer in AI-driven genomic analysis for personalized medicine. SeqOne's platform provides clinical decision-support tools that enable molecular laboratories to deliver fast, accurate, and scalable analysis of genetic data for applications in oncology, rare diseases, and multi-omics including pathogen detection.
Impressive Growth Trajectory
SeqOne has demonstrated remarkable growth momentum, achieving a threefold increase in customers over the past 12 months. The company now serves 140 active laboratory customers across 22 countries and projects processing over 110,000 patient analyses in 2025. This expansion reflects the growing global demand for precise and scalable genomic interpretation solutions in clinical settings.
"This fundraising is a testament to the incredible work of our team and the transformative potential of our platform in making personalized medicine a reality," said Martin Dubuc, CEO of SeqOne. "Our goal is to equip every molecular laboratory with the most advanced, intuitive, and reliable genomic analysis solutions."
Strategic Growth Initiatives
The new capital will fuel SeqOne's expansion across three core strategic pillars. First, the company will scale its international operations, building on its significant momentum in global markets. The funding will also accelerate SeqOne's U.S. market penetration following its Q1 2025 entry with a dedicated, HIPAA-compliant platform designed specifically for the American healthcare market.
Additionally, SeqOne plans to pursue targeted acquisitions to expand its capabilities and market share, following its recent acquisition of Life & Soft for multi-omics expertise. This acquisition strategy aims to broaden the company's technological scope and enhance its position in the competitive genomics landscape.
Market Leadership and Technology Innovation
SeqOne's AI-powered platform addresses critical needs in the Next-Generation Sequencing (NGS) data analysis market, where demand for automated, scalable solutions continues to accelerate. The company's technology enables molecular laboratories to process complex genomic data more efficiently, supporting clinical decision-making in oncology and rare disease diagnostics.
"SuperNova Invest is proud to partner with SeqOne, a company at the forefront of genomic analysis innovation," commented Rémi Spagnol, Investment Director at Supernova Invest. "Their impressive growth, cutting-edge technology, and visionary leadership team give us strong conviction in their ability to become a global category leader."
Strengthening Financial Foundation
The oversubscribed nature of the funding round demonstrates strong investor confidence in SeqOne's business model and growth prospects. The capital injection not only supports expansion plans but also strengthens the company's financial foundation, ensuring long-term stability for its growing customer base.
"This new capital injection not only empowers us to scale our international operations, particularly with our US launch, and to further enhance our technological leadership, but it also fortifies our financial foundations, ensuring our customers can depend on us as a steadfast partner for years to come," Dubuc added.
Recent Product Developments
SeqOne has continued to innovate its platform offerings, recently launching SomaHemato, a specialized hematology analysis tool. This addition includes a module designed to determine Immunoglobulin Heavy Chain Variable (IGHV) mutational status for Chronic Lymphocytic Leukemia (CLL), demonstrating the company's commitment to expanding its clinical applications.
The company's comprehensive approach to genomic analysis positions it well to capture the growing market for personalized medicine solutions, as healthcare providers increasingly rely on genetic data to inform treatment decisions and improve patient outcomes.
